Title:

Greater loss of female embryos during human pregnancy: A novel mechanism.

Subtitle:

Maternal tissues “interview” embryos during implantation, with female candidates disadvantaged by their greater genetic, metabolic, and hormonal distinctiveness

Author:

John F Mulley¹

Affiliation:

1. School of Natural Sciences, Bangor University, Deiniol Road, Bangor, LL57 2UW, United Kingdom

To whom correspondence should be addressed: j.mulley@bangor.ac.uk

Keywords: sex bias; miscarriage; abortion; stillbirth; stress; pregnancy; endometrium; implantation; placentation; ovarian asymmetry

Summary

Given an equal sex ratio at conception, we can only explain the excess of human males at birth by greater loss of females during pregnancy. I propose that the bias against females during human development is the result of a greater degree of genetic and metabolic “differentness” between female embryos and maternal tissues than for similarly aged males, and that successful implantation and placentation represents a threshold dichotomy, where the acceptance threshold shifts depending on maternal condition, especially stress. Right and left ovaries are not equal, and neither are the eggs and follicular fluid that they produce, and I further hypothesise that during times of stress, the implantation threshold is shifted sufficiently to favour survival of females, most likely those originating from the right ovary, and that this, rather than simply a greater loss of males, explains at least some of the variability in the human sex ratio at birth.

Introduction

The choosy uterus

Pregnancy can in part be viewed as a conflict between mother and offspring.^[1] Selection acts on maternal genes to limit the supply of resources to developing offspring so as to maximise (or at least stabilise) maternal fitness, whereas fetal genes are selected to maximise growth.^[1, 2] These selfish offspring may seek to maximise their own growth at the expense of future offspring, whereas maternal investment may vary with age, with younger mothers less likely, and older mothers more likely, to sacrifice their well-being for the benefit of their offspring.^[3, 4] Imprinting of maternal genes therefore serves to control the growth and/or function of the placenta. There is also potential conflict between maternal and paternal alleles, as fathers have an interest in improved survival of (their) current offspring even at the expense of future offspring, which may have a different father. With respect to offspring sex ratios, the Trivers and Willard Hypothesis proposes that as females deviate from the “average” condition they should bias the production of one sex over the other, driven by improved likelihood of producing grandchildren,^[5] and logic suggests that this sex ratio manipulation should occur early to minimise wasted maternal investment. In humans, the sex ratio at birth is male-biased, with around 1,055 males born per 1,000 females in England and Wales between 1927 and 2007 (Figure 1). Since implantation represents the first major instance of fetal-maternal conflict, I hypothesise that it is at this point that a large component of variation in the human sex ratio arises, facilitated by sensing of embryo quality by the uterine lining (endometrium),^[6–9] most specifically the degree of “*differentness*” from the mother. Implantation therefore represents a threshold dichotomy,^[10] where passing the threshold results in successful implantation and initiation of placentation (and at least a chance of further development) and failing results in loss, but where the threshold itself can vary within and between women. The mammalian implantation process is thought to have evolved from endometrial inflammation – a natural reaction of maternal tissues to a foreign body.^[11, 12] Whilst the initial stages of implantation are pro-inflammatory, post-implantation embryonic development requires an anti-inflammatory endometrial state, and there must therefore be a point of acceptance by the maternal tissues either at initial contact, or soon after as the embryo “invades” the endometrium and as the process of placentation progresses.^[7] The first few weeks of gestation place relatively little demand upon the mother and therefore involve little maternal investment, and so embryo quality control should occur early, with the fetal-maternal interface (i.e. the interaction between fetal ligands and maternal receptors) representing the front line in the battle between

invading trophoblast and defending maternal tissues. Indeed, discussion of early fetal-maternal interactions is full of references to embryonic “invasion” of the endometrium, and the literature is full of war-like references to “fighting lines”,^[13] “no man’s land”,^[14] and the embryo as a “deceitful and treacherous enemy”.^[15] A more appropriate comparison for the very earliest stages of implantation at or soon after the initiation of embryo-maternal contact may be an interview, where the embryo seeks to make a favourable impression.^[14] The evolution of deeper implantation in placental mammals facilitated more thorough vetting of offspring, and these deeper forms of implantation may have evolved to reduce the “ease” by which a mother may reject an embryos through sloughing of superficial layers of endometrium.^[14] This process, together with rapid evolution of placental proteins^[3] reflects the fetal-maternal arms race. How might this maternal vetting of embryos occur, and why might it preferentially target female embryos to result in a male-biased sex ratio at birth?

Male and female embryos differ from the very point of conception. Only males can express genes on the Y chromosome, and, prior to the completion of X chromosome inactivation, females can produce up to twice the amount of gene product for any gene encoded by the X chromosome. Male and female embryos therefore express different genes even at very early stages, varying from around 600 differentially-expressed genes in mouse blastocysts,^[16] to up to a third (2,921) of expressed transcripts in cow.^[17] Errors or delays in X chromosome inactivation, such as skewed (non-random) inactivation of the paternal or maternal copy, are likely to lead to increased fetal-maternal “differentness” and therefore preferential loss of female embryos. Indeed, such skewed inactivation has previously been implicated in recurrent miscarriage (typically defined as three or more consecutive miscarriages before 20 weeks), although evidence for this is often contradictory.^[18, 19] Male embryos grow faster,^[20, 21] and so a female embryo will be ready for implantation later than an identically-aged male, and is more likely to miss the implantation window when the endometrium is most receptive (a period of around 4 days, typically 6-8 days post-ovulation^[22]). Male and female embryos are also metabolically distinct, as females are thought to make more use of the pentose phosphate pathway, possibly because of an additional copy of the X-linked *G6PD1* gene,^[21] although others have cast doubt on this idea.^[23] Metabolism is likely the most fundamental difference between early male and female embryos, and certainly one of the most dynamic,^[24] and metabolically “quiet” embryos may survive better than more active ones.^[25–27] In this “quiet embryo hypothesis”, metabolic signatures of the embryo are assumed to reflect viability, for instance levels of DNA damage,^[26] with maternal selection against

metabolically-active (putatively less viable) embryos. Of course, this quest for quietness, if taken too far, would ultimately result in embryonic death, and so there must be a window of viability within which successful embryos must operate. Accepting that the endometrium acts as a biosensor to reject “unsuitable” embryos,^[6–8] and that there may be a “Goldilocks zone” of embryonic potential,^[28] females may be discriminated against from the very earliest stages of their development as early female embryos may be more different to their mother than their male counterparts. Although males have Y chromosome-specific genes that the mother does not herself possess, the X chromosome encodes more genes (846 to the 63 on the Y chromosome in Ensembl release GRCh38.p12), and prior to completion of X chromosome inactivation differential gene expression is therefore greater in females. Genes on sex chromosomes are known to regulate autosomal genes,^[23] and the greater number of X-linked genes in females will have a concomitantly larger effect on the number of downstream autosomal genes that are up- or down-regulated. Male and female embryos are both genetically distinct from their mother (i.e. encode paternally-derived genes), but again, because of the size of the X chromosome, females have a greater amount of paternal DNA (the X is 156Mb long, the Y just 57Mb, which may have relevance for the extent of imprinting), and a greater number of paternal genes.

A comprehensive study of the human sex ratio from conception to birth^[29] shows an initial large loss of male embryos in the first week or so, followed by a longer period of female-biased loss in the first trimester. As a result, the cohort sex ratio is male-biased from the end of the first trimester, and remains this way until the last few weeks of pregnancy, where male-biased stillbirth^[30] likely comes into play. The greatest number of female losses therefore occurs at or soon after implantation, and in the following weeks as placentation progresses. It is here that maternal-fetal contact is both established and, through placentation, extended, to reach the closest possible juxtaposition of maternal and fetal tissues and blood supplies, and this period also represents one of relatively limited fetal growth and maternal investment. It is no surprise that this should represent the “interview” period. Even once the interview is passed, the endometrium may still present a more hostile environment to female embryos, which may go some way to explaining sex differences in the male and female placenta, where female placentae are more sensitive to perturbation in the peri-conception period, and show reduced growth and a greater amount of variation in placental gene and protein expression.^[31, 32]

What is the extent of sex-biased loss in human pregnancy?

Whilst 10% of clinically-recognised pregnancies end in miscarriage, the true number is estimated to be much higher as many pregnancies are lost before they are identified, and up to one third of all pregnancies may end in spontaneous abortion (miscarriage).^[33–35] However, far higher values have been proposed.^[29, 36, 37] In 1975, Roberts and Lowe attempted to predict the annual number of conceptions in England and Wales in 1971,^[38] and suggested that up to 78% of conceptions were “lost” (unaccounted for in live birth and still birth records). Their analysis was based only on married women, hypothesised a mean frequency of coitus twice a week (one in four of which was unprotected), and did not include data for pregnancies ending in elective or therapeutic abortion. Using data from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)^[39] it is possible to refine these calculations somewhat, and these updated calculations suggest that the assumption that around a third of all conceptions might be lost is valid (Box 1, Table 1).

In England and Wales, all live births and stillbirths must be registered, and there is extensive historical data available on numbers of live births and stillbirths, including sex ratios (it should be noted however that in October 1992, the Stillbirth (Definition) Act 1992 changed the gestation cut-off for stillbirths from 28 or more weeks of gestation to 24 or more weeks, and so data from 1993 onwards is not comparable to previous years). In addition to extensive live birth and stillbirth data, the requirement that all practitioners in England and Wales who perform therapeutic or elective abortions must notify the Chief Medical Officer means that abortion statistics (including number of abortions by gestation week) are available going back to the late 1960’s. The stability of the overall sex ratio at birth (Figure 1) suggests that, in England and Wales at least, there is no sex-selective abortion, and the general increase in the number of legal abortions, and the lack of maternal deaths due to complications of illegal abortions^[40] also suggests that there are few if any unrecorded abortions. In England and Wales between 1993 and 2017 there were 16,489,289 maternities (a pregnancy resulting in the birth of one or more children including stillbirths, of which around 1.5% resulted in multiple births); 16,656,203 live births (8,114,739 female and 8,541,464 male, with on average 1,053 males born per 1,000 females); 86,714 stillbirths (41,059 female and 45,655 male, with on average 1,112 males stillborn per 1,000 females); 4,512,024 legal elective and therapeutic abortions, and 28,269,072 conceptions (assuming that 33% of conceptions result in spontaneous abortion (miscarriage) and that the recorded live birth, stillbirth and abortion figures therefore represent 67% of total conceptions). Historically, the male bias at birth was taken to result from the production of a greater proportion of males at conception, although more

recent data from *in vitro* fertilisation supports a balanced sex ratio at conception (see Orzack et al.^[29] for discussion), as does the simple mechanics of equal segregation of X and Y chromosomes during spermatogenesis. We can therefore reasonably conclude that the 28,269,072 conceptions comprised equal numbers of males and females. If males and females were also equally represented in the therapeutic and elective abortion dataset (i.e. the abortus sex ratio is 50:50), then 2,256,012 males and 2,256,012 females were aborted. However, more recent work^[29] supports a slightly female-biased cohort sex ratio during early pregnancy based on chorionic villus sampling, amniocentesis and induced abortions, and a conservative estimate of a 55:45 female:male sex ratio ≤ 12 weeks and 45:55 female:male ≥ 13 weeks might be more appropriate. In the study period, 4,044,380 therapeutic and elective abortions occurred ≤ 12 weeks of gestation and 467,644 occurred ≥ 13 weeks, with 2,435,740 girls aborted to 2,076,284 boys, for an average of 853 boys aborted per 1,000 girls (Figure 2, Supplemental table S1). Using these data, it is possible to deduce that 28,269,072 conceptions resulted in 7,014,131 spontaneous abortions (miscarriages) in England and Wales between 1993 and 2017, with on average 141,720 females and 138,845 boys lost each year, for an average miscarriage sex ratio of 980 boys per 1000 girls (Supplemental table S2). Significantly more girls are lost during pregnancy ($P < 0.00001$, Pearson's χ^2 test).

Stress, miscarriage, and variation in the sex ratio at birth

The human sex ratio at birth is not stable, and, in England and Wales between 1993-2017, ranged from 1,047 boys per 1,000 girls to 1,057 boys per 1,000 girls. The predicted miscarriage sex ratio over the same period, assuming equal numbers of males and females are conceived, ranged from 956 boys per 1,000 girls in 1993 to almost parity (999 boys per 1,000 girls) in 2006 (Figure 3). The variation seen in 2006 follows the July 7th 2005 terror attacks in London, and reflects the general observation that sex ratio varies following stressful events, and that parental hormone levels around conception in some ways influence the sex ratio of their offspring.^[41–43] Why might stress impact the human sex ratio at birth, and what exactly is changing?

The human stress response is mediated by the hypothalamic-pituitary-adrenal axis, and ultimately results in the release of glucocorticoid hormones (primarily cortisol) by the adrenal cortex. Interestingly, this process also results in release of progesterone by the adrenal cortex, and leads to increased circulating levels of progesterone in serum,^[44] most likely because progesterone and cortisol are both cholesterol derivatives, and progesterone is a precursor in the synthesis of cortisol. Similarly, both testosterone and estradiol are

cholesterol-derivatives, and so production of these hormones may also increase during the stress response. The link between cholesterol, hormones, and changes to the sex ratio at birth are hinted at in differences in ABO blood group cholesterol levels and sex ratios,^[45] and the link between cortisol and progesterone may also explain some seasonal variations in the human sex ratio at birth, as cortisol levels are known to vary throughout the year.^[46] Such a link may in future be detectable through measurement of circulating hormone levels during early pregnancy, especially if linked to early (<12 weeks) detection of fetal sex using non-invasive prenatal testing techniques (NIPT) and tracking of pregnancy outcome. If one of the factors involved in setting the threshold of acceptance for embryo implantation and peri-conception survival is the degree of differentness from the mother, then changes to hormone levels in the maternal circulation might alter the acceptance threshold, so embryos that previously would have been lost are now able to implant and survive. In particular, those female embryos produced from eggs originating in the right ovary, which would normally be rejected as too different might now survive in greater numbers.

216

217 Ovarian asymmetry

Humans demonstrate directional asymmetry, most obviously in the positioning of internal organs such as the heart, stomach and intestines. These asymmetries can ultimately be traced to determination of left-right axes during embryogenesis, dictated by left-biased ciliary flow and an ancient gene regulatory network involving *PITX2*, *NODAL* and *LEFTY*. Asymmetric *PITX2* expression is maintained and plays a role in subsequent organ development, and, in birds, underlies asymmetric development of the gonads, reaching its most extreme manifestation in the single (left) ovary and oviduct of many species.^[47–49] Among mammals, functional asymmetry of left and right ovaries has been reported from many species, including mice,^[50] shrews,^[51] gerbils,^[52] viscachia,^[53, 54] bats,^[55] and waterbuck.^[56] Although human gonadal asymmetry is perhaps most apparent in males, where the right testis is larger, the inherent directional asymmetry of vertebrate embryos demonstrates that the human left and right ovary are not equal from the earliest stages of development. In adults, this asymmetry manifests itself in anatomical relations (the left ovary lies adjacent to the sigmoid colon, the right nearer the appendix), venous drainage (the left ovary drains into the left renal vein, the right into the inferior vena cava^[57, 58]), and function. The right ovary may ovulate more frequently and favour pregnancy,^[59–63] and this elevated function possibly leaves the right ovary more susceptible to ovarian cancer,^[64, 65] cystic ovarian endometriosis,^[66] and ruptured corpus luteum.^[57, 67–69] Ectopic pregnancy

may also be more common on the right,^[70–72] and gonadal tissues are unevenly distributed in true hermaphrodites, with ovaries more common on the left, and testes/ovotestes more common on the right.^[73–75]

The data on functional asymmetry of human ovaries and possible differential susceptibility to disease are noisy with generally small effects, however, the consistent trends, coupled with developmental and anatomical asymmetries, tells us that we should not consider left and right ovaries as equals.

What implications might ovarian asymmetry have for human reproduction? There are hints in the literature that the right ovary might ovulate more, and favour pregnancy,^[59–63] but one possibility that is generally neglected is that differences between left and right ovaries might lead to variation in the human sex ratio at birth. It has long been recognised that more males are born than females in many populations, despite greater susceptibility of boys to stillbirth,^[30] (Figure 1). Whilst the sex ratio at birth is typically stable, and for the most part biased towards males, there is variation across populations, only some of which is likely due to sex-specific elective abortion.^[76] The remaining variation can seemingly be explained by demography, with those of African origin having lower sex ratios^[77, 78] (even becoming female-biased in some cases^[77]), latitude,^[79] and seasonality.^[80–82] Perhaps most interestingly, the sex ratio at birth can be perturbed by stressful events, such as the 1995 Kobe earthquake,^[83] famine,^[84] war,^[85–87] terrorist attacks,^[88–90] historic royal events,^[91] the Superbowl,^[92] and economic stress.^[93, 94] Such seasonal variation, coupled with the effects of stress, is evidence for hormonal influences on the human sex ratio at birth, and, indeed, it has previously been suggested that hormonal concentrations in parents around conception can alter sex ratios.^[41, 95] Once asymmetry of left and right ovaries is accepted, these influences may become easier to explain. The right and left ovaries differ in their venous drainage, and as a result, pressure in the right ovarian vein is higher than the left.^[57, 58] The right ovary therefore drains more slowly than the left, and so we can expect hormones to accumulate differentially, resulting in higher concentrations of estradiol, testosterone, progesterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), and cortisol on this side. These elevated concentrations are maintained, and perhaps boosted, by counter current exchange between ovarian veins and arteries.^[96] Prior to ovulation, a human oocyte is bathed in approximately 5ml of follicular fluid, containing estradiol and progesterone in concentrations roughly 500x and 1000x higher respectively than in serum,^[97–99] and the freedom of steroid hormones to move across membranes means that the oocyte will equilibrate to follicular fluid conditions prior to ovulation. Oocytes from the right and left ovaries will therefore experience different environments as folliculogenesis progresses, with levels of estradiol,

progesterone and others far in excess of maternal serum levels, and they will carry these hormones with them in their cytoplasm (and that of their companion cells) as they are released. At the same time, several millilitres of asymmetric follicular fluid is released, producing different microenvironments in the left and right fallopian tubes as the egg begins its journey towards fertilisation.

Ovarian asymmetry and human reproduction

Human sperm are attracted to follicular fluid.^[100, 101] More specifically, a subset of sperm cells undergo capacitation, and as a result demonstrate chemotaxis,^[102] with low levels of progesterone known to act as a chemoattractant.^[103–105] There is some debate regarding the role that follicular fluid plays *in vivo*, with evidence from animal studies suggesting $\leq 1\%$ of the follicular fluid released along with the egg actually enters the fallopian tube,^[106–109] equating to $\leq 50\mu\text{l}$ in humans. Others have suggested that follicular fluid is the major fluid constituent in fallopian tubes immediately post-ovulation, as the egg is carried into the tube via a wave of fluid.^[110] Follicular fluid that does not directly enter the fallopian tube is released into the peritoneal cavity immediately adjacent to the ovary, and the ruptured follicle may continue to secrete follicular fluid for a short time following ovulation (the developing follicle may also secrete hormones into the peritoneal cavity for a period *prior* to ovulation^[111]). There is therefore a pool of hormone-enriched fluid adjacent to the fimbria at the end of the fallopian tube before and after ovulation, and this may be drawn into the tube by ciliary flow^[112, 113] or enter adjacent blood vessels. Since the composition of fallopian tube fluid differs between left and right sides, and since sperm respond to progesterone concentrations in the picomolar range,^[102, 114] these differences may have implications for sperm chemotaxis. Given that the follicular microenvironment is virtually saturated with progesterone, the oocyte and its associated cumulus cells are likely equilibrated to follicular fluid conditions, and the oocyte-cumulus complex itself is also a source of chemoattractants, including progesterone.^[109, 114, 115] We therefore have a situation where the chemoattractant concentrations within oocyte-cumulus complexes differs between left and right sides, and where the fallopian tube fluid that bathes these complexes also differs.

With this in mind, there are several ways that ovarian asymmetry (as demonstrated by variation in hormonal concentrations in follicular fluid from left and right ovaries) might influence human fertility. Firstly, progesterone can inhibit ciliary beating in the fallopian tube,^[116, 117] and so egg motility may differ between the left and right tubes, with extended migration times reducing the possibility of “healthy” sperm reaching

the egg. Secondly, different hormone/chemoattractant concentrations on the left and right may affect sperm chemotaxis, either positively, through improved or earlier attraction of sperm, or negatively, through saturation of receptors. Saturated receptors can no longer detect increases in chemoattractant concentration, rendering chemotaxis impossible, and studies of human sperm cell responses to progesterone have indeed shown that high concentrations are ineffective, and that sperm more readily respond to concentrations in the picomolar range.^[102, 114] These effects may operate over both long (from the sperm reservoir to the oocyte-cumulus complex) or short (within the oocyte-cumulus complex) distances. Similarly, X and Y chromosome-bearing sperm may respond differently to signals from the right and left. There has been much debate over morphological or behavioural differences between X and Y chromosome-bearing sperm, with some suggesting that those carrying the smaller Y chromosome may have a smaller head size and swim faster (and potentially further) than those bearing the larger X chromosome.^[118, 119] The difference in DNA content between X and Y chromosome-bearing sperm is roughly 3%, and, although small, it does seem likely that this has at least some influence on size and/or shape of the sperm head.^[21, 120–122] Sperm carrying X or Y chromosomes may therefore have either variable numbers of chemoreceptors such as CatSper^[123, 124] and hOR17-4,^[125] or these receptors may be distributed differently across the sperm head. A higher number of receptors on larger X chromosome-bearing sperm might improve sensitivity, whilst a lower number on those carrying a Y may make them more easily saturated. Variability in receptor distribution across larger or smaller sperm heads might also improve directionality, or simply improve sensitivity by widening the detection window. Most importantly, the different intrinsic hormone concentrations of eggs originating in the left and right ovaries might impact embryonic implantation, placentation, and post-implantation survival and especially greater survival of female embryos during times of stress when the maternal acceptance threshold shifts in their favour.

The literature concerning the human sex ratio at birth is very male-centric. Discussion of variation in sex ratio, and especially declines, typically assumes that this is the result of a greater loss of males (the “fragile male” idea^[126–128]), possibly because most male losses occur later in development, and so are more visible. A similar result can of course also be explained by more females surviving than would usually be the case.^[129] Such increased survival can affect the sex ratio at birth in several ways, most obviously with a greater number of female live births, but also by impacting subsequent pregnancies. In those actively trying to conceive, a female embryo lost early (at or soon after implantation) might have been replaced by a male in a

subsequent cycle, but survival of the female embryo removes that mother from the pool of potential reproducers for the duration of the pregnancy, and sometime beyond. Reproductive behaviour may also be important, particularly in terms of stopping rules,^[130] where couples desiring a child of a specific sex stop reproducing once this is achieved, or where couples might wish for a child of each sex, and continue reproducing until this is achieved. In conditions which favour survival of females, those seeking a girl might therefore stop reproducing after one pregnancy, and those who seek a boy and a girl would stop if they already have a boy. Conversely, those seeking a boy who already have one girl might continue to reproduce after having another, and, if the stressful conditions endure, may continue to have girls. However, it must be kept in mind that changes to the human sex ratio at birth are typically small, varying only between a low of 51.02:48.98% male:female in 1927 to a high of 51.58:48.42% male:female in 1973, based on live birth data for England and Wales from 1927-2017. In the 62,454,461 live births recorded during this period, only 1,685,618 more boys than girls were born. If slightly more boys were conceived (i.e. if the primary sex ratio at conception was not exactly equal), then this miscarriage sex bias would disappear – althoughy we would then need a mechanism which would favour greater conception of boys. Whilst ovarian asymmetry and a threshold dichotomy of implantation and placentation success predicated upon uterine biosensing may not account for all of the observed variation in miscarriage sex, it does represent a novel mechanism by which we can explain existing data, such as the influence of maternal hormones around the time of conception, and the impact of stressful events and seasonality on the human sex ratio at birth.

Conclusions

Ovarian asymmetry is a neglected aspect of reproductive biology. It is rare to find a scientific publication dealing with embryos produced by assisted reproductive technology or the composition of follicular fluid that identifies from which ovary the study materials were sourced. Similarly, studies of implantation rarely, if ever, identify the sex of embryos concerned. Research in adult humans, or using animals, is required to report the participant sex, and it is perhaps time for greater awareness of embryonic sex and ovary-of-origin in the study of early human development. A greater appreciation of ovarian asymmetry may also be necessary for explaining variation within and between women (Box 2). Similarly, consideration of testicular asymmetry, and that of the uterus and fallopian tubes, may also be overdue, as early developmental asymmetries likely impact all of these structures.

More girls are lost during pregnancy than boys, and as a result the human sex ratio at birth is biased towards males. Male and female embryos are not equal from the very moment of conception, and it should be no surprise that these differences might influence some of the most important aspects of mammalian development, such as implantation and placentation. The greater genetic and metabolic “differentness” of female embryos, at least prior to the development of functional gonads, may count against them in the threshold dichotomy^[10] of acceptance or rejection by maternal tissues. Such discrimination may ultimately work in their favour however, if it follows a pattern similar to that in ‘reverse’ imprinting,^[131, 132] where expression of maternal alleles might be favoured if elevated gene expression increases the possibility of spontaneous abortion, but leads to an increase in robustness (increased growth and pre- and post-natal survival) of survivors. If losses occur early in pregnancy, minimal resources have been invested and cost to the mother is limited. Boys exhibit greater infant mortality than girls^[133] (and higher stillbirth rates) and so it may be that the greater loss of girls earlier in pregnancy actually explains their later robustness.

Acknowledgements

I would like to thank Tom Brekke, Daniel Brison, Henry Leese, John Aplin, and David Steinsaltz for comments and advice on the manuscript, and Gudrun Rieck for general discussion. Comments from Professor Bill James and two anonymous reviewers greatly improved the final manuscript.

References

1. D. Haig. *Q. Rev. Biol.* **1993**, 68, 495.
2. T. Moore, D. Haig. *Trends Genet.* **1991**, 7, 45.
3. E.B. Chuong, W. Tong, H.E. Hoekstra. *Mol. Biol. Evol.* **2010**, 27, 1221.
4. N. Peacock. *Hum. Nat.* **1991**, 2: 351–85.
5. R.L. Trivers, D.E. Willard. *Science* **1973**, 179, 90.
6. J.D. Aplin, P.T. Ruane. *J Cell Sci* **2017**, 130, 15.
7. N.S. Macklon, J.J. Brosens. *Biol. Reprod.* **2014**, 91, 91.
8. J.J. Brosens, M.S. Salker, G. Teklenburg, J. Nautiyal, S. Salter, E.S. Lucas, J.H. Steel, M. Christian, Y.-W. Chan, C.M. Boomsma. *Sci. Rep.* **2014**, 4, 3894.
9. S. Quenby, G. Vince, R. Farquharson, J. Aplin. *Hum. Reprod.* **2002**, 17, 1959.

- 378 10. S. Wright. *Evolution and the Genetics Of Populations, Volume 1: Genetic and Biometric Foundations*.
379 University of Chicago Press, **1968**.
- 380 11. O.W. Griffith, A.R. Chavan, S. Protopapas, J. Maziarz, R. Romero, G.P. Wagner. *Proc. Natl. Acad. Sci.*
381 *U. S. A.* **2017**, *114*, E6566.
- 382 12. A.R. Chavan, O.W. Griffith, G.P. Wagner. *Curr. Opin. Genet. Dev.* **2017**, *47*, 24.
- 383 13. R.W. Johnstone. *BJOG An Int. J. Obstet. Gynaecol.* **1914**, *25*, 231.
- 384 14. D.A. Haig, in *Placental Bed Disorders: Basic Science and its Translation to Obstetrics*, (Ed: R Pjenborg,
385 I Brosens, R. Romero), Cambridge University Press. **2010** pp. 165.
- 386 15. N. Ashary, A. Tiwari, D. Modi. *Endocrinology* **2018**, *159*, 1188.
- 387 16. S. Kobayashi, A. Isotani, N. Mise, M. Yamamoto, Y. Fujihara, K. Kaseda, T. Nakanishi, M. Ikawa, H.
388 Hamada, K. Abe. *Curr. Biol.* **2006**, *16*, 166.
- 389 17. D. Rath, D. Rizos, P. Bermejo-Alvarez, A. Gutierrez-Adan, P. Lonergan. *Proc. Natl. Acad. Sci.* **2010**,
390 *107*, 3394.
- 391 18. Y. Sui, Q. Chen, X. Sun, *Reprod. Biomed. Online.* **2015**, *31*,140-8.
- 392 19. W. A. Hogge, T. L. Prosen. M. C. Lanasa, H. A. Huber, *Am. J. Obstet. Gynecol.* 2007, *196*, 384.e1.
- 393 20. A. Gutiérrez-Adán, M. Perez-Crespo, R. Fernandez-Gonzalez, M.A. Ramirez, P. Moreira, B. Pintado, P.
394 Lonergan, D. Rizos. *Reprod. Domest. Anim.* **2006**, *41*, 54.
- 395 21. E.Z. Cameron, A.M. Edwards, L.M. Parsley. *Ann. N. Y. Acad. Sci.* **2017**, *1389*, 147.
- 396 22. P.A. Bergh, D. Navot. *Fertil. Steril.* **1992**, *58*, 537.
- 397 23. S. Pérez-Cerezales, P. Ramos-Ibeas, D. Rizos, P. Lonergan, P. Bermejo-Alvarez, A. Gutiérrez-Adán.
398 *Reproduction* **2018**, *155*, R39.
- 399 24. H.J. Leese. *Reproduction* **2012**, *143*, 417.
- 400 25. C.G. Baumann, D.G. Morris, J.M. Sreenan, H.J. Leese. *Mol. Reprod. Dev.* **2007**, *74*, 1345.
- 401 26. R.G. Sturme, J.A. Hawkhead, E.A. Barker, H.J. Leese. *Hum. Reprod.* **2008**, *24*, 81.
- 402 27. H.J. Leese. *Bioessays* **2002**, *24*, 845.
- 403 28. D.R. Brison, H.J. Leese, K. Lundin, F. Guerif, V. Allgar, R.G. Sturme. *Mol. Reprod. Dev.* **2016**, *83*,
404 748.
- 405 29. S.H. Orzack, J.W. Stubblefield, V.R. Akmaev, P. Colls, S. Munné, T. Scholl, D. Steinsaltz, J.E.
406 Zuckerman. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112*, E2102.

- 407 30. D. Mondal, T.S. Galloway, T.C. Bailey, F. Mathews. *BMC Med.* **2014**, *12*, 220.
- 408 31. J.I. Kalisch-Smith, D.G. Simmons, H. Dickinson, K.M. Moritz. *Placenta* **2017**, *54*, 10.
- 409 32. V.L. Clifton. *Placenta* **2010**, *31*, S33.
- 410 33. A.J. Wilcox, C.R. Weinberg, J.F. O'Connor, D.D. Baird, J.P. Schlatterer, R.E. Canfield, E.G. Armstrong,
411 B.C. Nisula. *N. Engl. J. Med.* **1988**, *319*, 189.
- 412 34. A.J. Wilcox, D.D. Baird, C.R. Weinberg. *N. Engl. J. Med.* **1999**, *340*, 1796.
- 413 35. X. Wang, C. Chen, L. Wang, D. Chen, W. Guang, J. French. *Fertil. Steril.* **2003**, *79*, 577.
- 414 36. G.E. Jarvis. *F1000Research* **2016**, *5*, 2765.
- 415 37. G.E. Jarvis. *F1000Research* **2016**, *5*, 2083.
- 416 38. C. Roberts, C. Lowe. *Lancet* **1975**, *305*, 498.
- 417 39. C.H. Mercer, C. Tanton, P. Prah, B. Erens, P. Sonnenberg, S. Clifton, W. Macdowall, R. Lewis, N. Field,
418 J. Datta, A.J. Copas, A. Phelps, K. Wellings, A.M. Johnson. *Lancet* **2013**, *382*, 1781.
- 419 40. R. Cantwell, T. Clutton-Brock, G. Cooper, A. Dawson, et al. *BJOG An Int. J. Obstet. Gynaecol.* **2011**,
420 *118.1*, 1.
- 421 41. W.H. James. *J. Theor. Biol.* **1996**, *180*, 271.
- 422 42. K.J. Navara. *J. Comp. Physiol. B* **2010**, *180*, 785.
- 423 43. K.J. Navara. *Integr. Comp. Biol.* **2013**, *53*, 877.
- 424 44. A.Y. Herrera, S.E. Nielsen, M. Mather. *Neurobiol. Stress* **2016**, *3*, 96.
- 425 45. T.M. Allan. *Reproduction* **1975**, *43*, 209.
- 426 46. A.H. Garde, Å.M. Hansen, B. Karlson, B. Larsson, R. Persson, K. Österberg, P. Ørbæk. *Chronobiol. Int.*
427 **2008**, *25*, 923.
- 428 47. J. Rodríguez-León, C.R. Esteban, M. Martí, B. Santiago-Josefat, I. Dubova, X. Rubiralta, J.C.I.
429 Belmonte. *Proc. Natl. Acad. Sci.* **2008**, *105*, 11242.
- 430 48. S. Guioli, S. Nandi, D. Zhao, J. Burgess-Shannon, R. Lovell-Badge, M. Clinton. *Sex Dev.* **2014**, *8*, 227.
- 431 49. S. Guioli, R. Lovell-Badge. *Development* **2007**, *134*, 4199.
- 432 50. J.L. Wiebold, W.C. Becker. *J. Reprod. Fertil.* **1987**, *79*, 125.
- 433 51. S. Hellwing, B. Funkenstein. *J. Reprod. Fertil.* **1977**, *49*, 163.
- 434 52. M.M. Clark, M. Ham, B.G. Galef. *Reproduction* **1994**, *101*, 393.
- 435 53. O.P. Pearson. *Am. J. Anat.* **1949**, *84*, 143.

- 436 54. B.J. Weir. *J. Zool.* **1971**, 164, 463.
- 437 55. W.A. Wimsatt. *J. Reprod. Fertil.* **1979**, 56, 345.
- 438 56. C.A. Spinage. *J. Reprod. Fertil.* **1969**, 18, 445.
- 439 57. L.C. Tang, H.K. Cho, S.Y. Chan, V.C. Wong. *J. Reprod. Med.* **1985**, 30, 764.
- 440 58. R. Wang, Y. Yan, S. Zhan, L. Song, W. Sheng, X. Song, X. Wang. *Medicine (Baltimore)*. **2014**, 93, e53.
- 441 59. G. Potashnik, V. Insler, I. Meizner, M. Sternberg. *Br. Med. J. (Clin. Res. Ed)*. **1987**, 294, 219.
- 442 60. M. Fukuda, K. Fukuda, C.Y. Andersen, A.G. Byskov. *Hum. Reprod.* **2000**, 15, 1921.
- 443 61. I. Järvelä, S. Nuojua-Huttunen, H. Martikainen. *Hum. Reprod.* **2000**, 15, 1247.
- 444 62. M. Fukuda, K. Fukuda, K. Tatsumi, T. Shimizu, M. Nobunaga, A.G. Byskov, C. Yding Andersen. *Fertil.*
445 *Steril.* **2011**, 95, 2545.
- 446 63. K.C. Lan, F.J. Huang, Y.C. Lin, F.T. Kung, T.H. Lan, S.Y. Chang. *Fertil. Steril.* **2010**, 93, 2269.
- 447 64. P. Vercellini, G. Scarfone, G. Bolis, G. Stellato, S. Carinelli, P.G. Crosignani. *BJOG An Int. J. Obstet.*
448 *Gynaecol.* **2000**, 107, 1155.
- 449 65. F. Parazzini, L. Luchini, P. Vercellini, G. Bolis, M. Dindelli. *BMJ* **1992**, 304, 1180.
- 450 66. P. Vercellini, G. Aimi, O. De Giorgi, S. Maddalena, S. Carinelli, P.G. Crosignani. *BJOG An Int. J.*
451 *Obstet. Gynaecol.* **1998**, 105, 1018.
- 452 67. J.G. Hallatt, C.H. Steele, M. Snyder. *Am. J. Obstet. Gynecol.* **1984**, 149, 5.
- 453 68. L.T. Hibbard. *Am. J. Obstet. Gynecol.* **1979**, 135, 666.
- 454 69. A. Raziel, R. Ron-El, M. Pansky, S. Arieli, I. Bukovsky, E. Caspi. *Eur. J. Obstet. Gynecol. Reprod. Biol.*
455 **1993**, 50, 77.
- 456 70. R. Langer, A. Raziel, R. Ron-El, A. Golan, I. Bukovsky, E. Caspi. *Fertil. Steril.* **1990**, 53, 227.
- 457 71. P.F. Brenner, S. Roy, D.R. Mishell. *JAMA* **1980**, 243, 673.
- 458 72. C.J. Crowe, K. Vigneswaran, S. Merritt, J. Hamilton. *Ultrasound Obstet. Gynecol.* **2012**, 40, 188.
- 459 73. G. Krob, A. Braun, U. Kuhnle. *Eur. J. Pediatr.* **1994**, 153, 2.
- 460 74. U. Mittwoch. *Mol. Genet. Metab.* **2000**, 71, 405.
- 461 75. W.A. van Niekerk, A.E. Retief. *Hum. Genet.* **1981**, 58, 117.
- 462 76. M.L. Urquia, R. Moineddin, P. Jha, P.J. O'Campo, K. McKenzie, R.H. Glazier, D.A. Henry, J.G. Ray.
463 *CMAJ* **2016**, 188, E181.
- 464 77. M. Garenne. *South. African J. Demogr.* **2004**, 9, 91.

- 465 78. A.M. Branum, J.D. Parker, K.C. Schoendorf. *Hum. Reprod.* **2009**, 24, 2936.
- 466 79. K.J. Navara. *Biol. Lett.* **2009**, 5, 524.
- 467 80. A. Cagnacci, A. Renzi, S. Arangino, C. Alessandrini, A. Volpe. *Hum. Reprod.* **2003**, 18, 885.
- 468 81. E. Van Cauter, A. Cagnacci. *Fertil. Steril.* **2005**, 84, 246.
- 469 82. N. Rojansky, A. Brzezinski, J.G. Schenker. *Hum. Reprod.* **1992**, 7, 735.
- 470 83. M. Fukuda, K. Fukuda, T. Shimizu, H. Møller. *Hum. Reprod.* **1998**, 13, 2321.
- 471 84. S. Song. *Proc. R. Soc. B Biol. Sci.* **2012**, 279, 2883.
- 472 85. M. Ansari-Lari, M. Saadat. *J. Epidemiol. Community Heal.* **2002**, 56, 622.
- 473 86. B. Zorn, V. Šučur, J. Stare, H. Meden-Vrtovec. *Hum. Reprod.* **2002**, 17, 3173.
- 474 87. A. Kemkes. *Am. J. Hum. Biol.* **2006**, 18, 806.
- 475 88. R. Dobson. *BMJ* **2006**, 333, 516.
- 476 89. R. Catalano, T. Bruckner, J. Gould, B. Eskenazi, E. Anderson. *Hum. Reprod.* **2005**, 20, 1221.
- 477 90. G. Masukume, S.M. O'Neill, A.S. Khashan, L.C. Kenny, V. Grech. *Acta Medica (Hradec Kral. Czech*
478 *Republic)* **2017**, 60, 59.
- 479 91. V. Grech. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2015**, 191, 57.
- 480 92. V. Grech, D. Zammit. *Early Hum. Dev.* **2018**, 128, 86.
- 481 93. R.A. Catalano, T. Bruckner. *Soc. Sci. Med.* **2005**, 60, 537.
- 482 94. R.A. Catalano. *Hum. Reprod.* **2003**, 18, 1972.
- 483 95. W.H. James. *J. Biosoc. Sci.* **2011**, 43, 167.
- 484 96. N. Einer-Jensen, R.H.F. Hunter. *Reproduction* **2005**, 129, 9.
- 485 97. B.A. Stone, P.C. Serafini, J.H. Batzofin, P. Quinn, J.F.P. Kerin, R.P. Marrs. *Fertil. Steril.* **1988**, 50, 102.
- 486 98. M. Bächler, D. Menshykau, C. De Geyter, D. Iber. *MHR Basic Sci. Reprod. Med.* **2014**, 20, 208.
- 487 99. M.M. Emori, R. Drapkin. *Reprod. Biol. Endocrinol.* **2014**, 12, 60.
- 488 100. D. Ralt, M. Manor, A. Cohen-Dayag, I. Tur-Kaspa, I. Ben-Shlomo, A. Makler, I. Yuli, J. Dor, S.
489 Blumberg, S. Mashiach. *Biol. Reprod.* **1994**, 50, 774.
- 490 101. A. Cohen-Dayag, I. Tur-Kaspa, J. Dor, S. Mashiach, M. Eisenbach. *Proc. Natl. Acad. Sci.* **1995**, 92,
491 11039.
- 492 102. M. Eisenbach, L.C. Giojalas. *Nat. Rev. Mol. Cell Biol.* **2006**, 7, 276.

- 493 103. M.E. Teves, H.A. Guidobaldi, D.R. Uñates, R. Sanchez, W. Miska, S.J. Publicover, A.A.M. Garcia,
494 L.C. Giojalas. *PLoS One* **2009**, *4*, e8211.
- 495 104. B.S. Jaiswal, I. Tur-Kaspa, J. Dor, S. Mashiach, M. Eisenbach. *Biol. Reprod.* **1999**, *60*, 1314.
- 496 105. R. Oren-Benaroya, R. Orvieto, A. Gakamsky, M. Pinchasov, M. Eisenbach. *Hum. Reprod.* **2008**, *23*,
497 2339.
- 498 106. K.P. Brussow. *Theriogenology* **1998**, *49*, 340.
- 499 107. R.H.F. Hunter, H.H. Petersen, T. Greve. *Mol. Reprod. Dev. Inc. Gamete Res.* **1999**, *54*, 283.
- 500 108. C. Hansen, A. Srikanthakumar, B.R. Downey. *Mol. Reprod. Dev.* **1991**, *30*, 148.
- 501 109. F. Sun, A. Bahat, A. Gakamsky, E. Girsh, N. Katz, L.C. Giojalas, I. Tur-Kaspa, M. Eisenbach. *Hum.*
502 *Reprod.* **2005**, *20*, 761.
- 503 110. R.A. Lyons, E. Saridogan, O. Djahanbakhch. *Hum. Reprod.* **2006**, *21*, 52.
- 504 111. P.R. Koninckx, G. Verhoeven, H. Van Baelen, W.D. Lissens, P. De Moor, I.A. Brosens. *J. Clin.*
505 *Endocrinol. Metab.* **1980**, *51*, 1239.
- 506 112. R. Kurzrok, L. Wilson, C. Birnberg. *Fertil. Steril.* **1953**, *4*, 479.
- 507 113. R.H.F. Hunter, E. Cicinelli, N. Einer-Jensen. *Acta Obstet. Gynecol. Scand.* **2007**, *86*, 260.
- 508 114. M.E. Teves, F. Barbano, H.A. Guidobaldi, R. Sanchez, W. Miska, L.C. Giojalas. *Fertil. Steril.* **2006**,
509 *86*, 745.
- 510 115. T. Maeda, M. Shimada, T. Terada, Y. Yamashita, T. Okazaki. *Biol. Reprod.* **2004**, *68*, 1193.
- 511 116. M. Ezzati, O. Djahanbakhch, S. Arian, B.R. Carr. *J. Assist. Reprod. Genet.* **2014**, *31*, 1337.
- 512 117. A. Bylander, M. Nutu, R. Wellander, M. Goksör, H. Billig, D.G.J. Larsson. *Reprod. Biol.*
513 *Endocrinol.* **2010**, *8*, 48.
- 514 118. L.B. Shettles. *Nature* **1960**, *186*, 648.
- 515 119. L.B. Shettles. *Obstet. Gynecol.* **1961**, *18*, 122.
- 516 120. K. Cui. *Mol. Hum. Reprod.* **1997**, *3*, 61.
- 517 121. J.O. Carvalho, L.P. Silva, R. Sartori, M.A.N. Dode. *PLoS One* **2013**, *8*, e59387.
- 518 122. J.H. Check, D. Katsoff. *Hum. Reprod.* **1993**, *8*, 211.
- 519 123. P. V Lishko, I.L. Botchkina, Y. Kirichok. *Nature* **2011**, *471*, 387.
- 520 124. T. Strücker, N. Goodwin, C. Brenker, N.D. Kashikar, I. Weyand, R. Seifert, U.B. Kaupp. *Nature*
521 **2011**, *471*, 382.

522 125. M. Spehr, G. Gisselmann, A. Poplawski, J.A. Riffell, C.H. Wetzel, R.K. Zimmer, H. Hatt. *Science*
523 **2003**, 299, 2054.

524 126. L. Cruciani, R.D. Sarti, G.C. Di Renzo, A.M. Cutuli, A. Rosati. *Gend. Med.* **2007**, 4, 19.

525 127. S. Kraemer. *Bmj* **2000**, 321, 1609.

526 128. C.E. Boklage. *Hum. Reprod.* **2005**, 20, 583.

527 129. R.A. Catalano, K. Saxton, T. Bruckner, S. Goldman, E. Anderson. *J. Theor. Biol.* **2009**, 257, 475.

528 130. W.H. James. *Hum. Reprod.* **2002**, 15, 1184.

529 131. Y. Iwasa, A. Mochizuki, Y. Takeda. *Evol. Ecol. Res.* **1999**, 1, 129.

530 132. Y. Iwasa. *Curr Top Dev Biol.* **1998**, 40, 255.

531 133. R. Pongou. *Demography* **2013**, 50, 421.

532 134. K. Wellings, K.G. Jones, C.H. Mercer, C. Tanton, S. Clifton, J. Datta, A.J. Copas, B. Erens, L.J.
533 Gibson, W. Macdowall, P. Sonnenberg, A. Phelps, A.M. Johnson. *Lancet* **2013**, 382, 1807.

534 135. P. Braude, P. Rowell. *BMJ* **2003**, 327, 852.

535

536

537

538

539

540

541

542

543

544

545

Figure 1. Live birth and stillbirth sex ratio in England and Wales, 1927-2017. On average 1,055 males were born per 1,000 females, and there are no years where more females are born than boys. The definition of stillbirth changed from 28 weeks of gestation to 24 weeks of gestation in 1992, and on average 1,133 boys were stillborn per 1,000 girls between 1927 and 1992, and 1,112 per 1,000 between 1993 and 2017. In the entire dataset, there are only three years where more girls were stillborn than boys (1974, 1975, 2016).

Figure 2. Sex ratio of therapeutic and elective abortions in England and Wales, 1993-2017, determined on the assumption that early (≤ 12 weeks) abortions are biased towards females (55:45) and later abortions (≥ 13 weeks) are biased towards males (45:55).

Figure 3. Relative miscarriage sex bias in England and Wales, 1993-2017, calculated as $1 - (\text{females miscarried} / \text{males miscarried})$, calculated if 33% of all conceptions result in miscarriage. A value of 0 indicates no bias, a positive value would show male bias, and a negative value a female bias. Miscarriages are biased towards females in every year of this 25 year dataset, with a marked decrease in the miscarriage sex ratio around 2005-2006, following the 7th July 2005 terrorist bombings in London, and a smaller dip in 2009 that may be due to the 2008 financial crisis.

Table 1. Theoretical prediction of the number of miscarried products of conception in England and Wales in 2012. Sexual habits are based on Natsal-3^[39] for women aged 16-44, and the remaining data are from ONS statistical datasets as described in the text. The predicted miscarriage rate is 43% overall, or 38% for women aged 20-39 (responsible for the majority of live births, stillbirths and abortions).

	Age					
	Under 20	20-24	25-29	30-34	35-39	All
Number of women	1362919	1893629	1925992	1898383	1803418	8884341
Annual acts of vaginal sex (assuming 44 per woman per year)	59968436	83319676	84743648	83528852	79350392	390911004
Annual acts of unprotected vaginal sex (assuming one in six is unprotected)	9994739	13886613	14123941	13921475	13225065	65151834
Unprotected acts occurring within 48-hour period around ovulation (i.e. 1/14)	713910	991901	1008853	994391	944648	4653702
Assume one in three of these results in fertilisation	237970	330634	336284	331464	314883	1551234
Number of live births to these women	33815	132456	202370	216242	114797	699680
Number of stillbirths to these women	217	669	936	912	601	3118
Number of elective and therapeutic abortions to these women	30539	54558	41882	30353	18523	145316
Estimated loss	173399	142951	91096	83957	180962	672364
Percentage loss	73%	43%	27%	25%	57%	43%

Box 1. Calculating the number of missing conceptions.

Natsal-3^[39] suggests that women aged 16-44 in the survey period (6th September 2010 – 31st August 2012) had on average 4.9 occasions of sexual intercourse (defined as vaginal, oral or anal intercourse) in the preceding 4 weeks, of which 69% included vaginal sex (defined as a man's penis in a woman's vagina). The frequency of sexual intercourse for this age group is likely nearer 1.2 occasions per week, with 0.85 instances of vaginal sex per week. The annual frequency (i.e. for 52 weeks) of vaginal sex for women aged 16-44 in the survey period was therefore 44.2, not the 104 previously used by Roberts and Lowe.^[38] The proportion of unprotected acts of coitus during the survey period is also lower than the 25% estimate of Roberts and Lowe, and is likely nearer 5-7% for women aged 16-44,^[134] increasing to around 10% if less effective methods of contraception are included, or to 1/6 if some consideration is given to those trying to conceive or who were already pregnant. The number of unprotected instances of vaginal sex per woman per year is therefore around 7, and, of these, 1/14 will occur within 48 hours of ovulation. Given a fertilisation rate of around 60% in *in vitro* fertilisation,^[135] where sperm quality and quantity is likely higher than that of a "normal" ejaculate at the point of fertilisation *in vivo*, a fertilisation rate of one in three seems reasonable. The Office for National Statistics mid-year population estimate for mid-2012 predicted that there were 8,884,341 women between the ages of 16-39 in England and Wales, and so the estimated the number of "missing" conceptions (i.e. those not accounted for in the relevant live birth, stillbirth, and legal therapeutic and elective abortion statistics) for women aged 16-39 in 2012 was 43%. For women aged 20-39 (responsible for 91% of all live births, 88% of stillbirths and 78% of abortions), the average rate of loss was 38% (Table 1). Given the inherent uncertainty in these calculations, an estimate that around a third of all conceptions are lost seems reasonable.

Box 2. Quantifying ovarian asymmetry

We know that the right and left ovaries are not equal. They originate on different sides of an asymmetric embryo, and lie in different sides in a directionally asymmetric adult. Differences in venous relations suggest that rates of drainage will vary, and we might therefore expect that levels of various hormones and metabolites might also vary. What is needed now is direct measurement of these variations. Whilst this may seem a relatively simple experiment, requiring only collection of follicular fluid from the left and right ovaries of a large number of women during assisted-reproduction, it is complicated by the fact that every ovulation changes the ovary, forever, converting a primordial follicle into a fibrous, scar-like corpus albicans. However, ovaries do not endlessly accumulate corpora albicantia, and those of premenopausal women undergo a process of fibroblastic replacement, ultimately forming a new section of ovarian connective tissue (stroma). Given different patterns of right/left ovulation between women, and with variable gaps related to childbirth or contraception, it becomes clear that we should be very careful when comparing ovaries between even age-matched women. How then might we quantify ovarian asymmetry in the face of differential patterns and numbers of ovulations? The simplest approach seems to be to go earlier, and to investigate inherent ovarian asymmetry before the onset of puberty, through measurement of levels of hormones and metabolites in the left and right ovaries with respect to circulating levels.

Supplemental information

Supplemental methods

Data for numbers of maternities, live births and stillbirths, including numbers of males and females, were collected from the Office for National Statistics (<https://www.ons.gov.uk/>) ‘Review of the Registrar General on births and patterns of family building in England and Wales’, Series FM1 (numbers 22-37, covering 1993-2008), the ‘Characteristics of Birth 2, England and Wales’ dataset (2009-2013), the ‘Birth characteristics dataset’ (2014-2016), and the ‘Summary of key birth statistics, 1838 to 2017’. Data on numbers of legal abortions from 2011-2017 were obtained from the Department of Health and Social Care (DHSC) ‘Abortion statistics, England and Wales’ collection (<https://www.gov.uk/government/collections/abortion-statistics-for-england-and-wales>), and for 1993-2010 from the UK Government Web Archive (<http://www.nationalarchives.gov.uk/webarchive/>). Numbers of stillbirths by age of mother for 2012 were obtained from the ‘Child Mortality Statistics 2012’ dataset (<https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/datasets/childmortalitystatisticschildhoodinfantandperinatalchildhoodinfantandperinatalmortalityinenglandandwales>), and England and Wales population data were obtained from the ‘MYE2: Population Estimates by single year of age and sex for local authorities in the UK, mid-2012’ (<https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland>).

Gestation week data is variable across the abortion dataset, and so statistics were pooled into abortions occurring either ≤ 12 weeks or ≥ 13 weeks. A comprehensive study of the human sex ratio from conception to birth^[29] supports a female-biased cohort sex ratio during early pregnancy based on chorionic villus sampling, amniocentesis and induced abortions, and I have therefore chosen a conservative estimate of a 55:45 female:male sex ratio ≤ 12 weeks and 45:55 female:male ≥ 13 weeks. Using these values, I calculated the number of male and female abortuses each year.

Adding together the total number of live births, stillbirths and legal abortions provided the number of pregnancies, and accepting that these represent 67% of actual conceptions (i.e. the probability that a conception resulted in miscarriage was 33%) determined the relevant number of conceptions. If the primary sex ratio is equal, then equal numbers of males and females are conceived, and subtraction of the known

numbers of live and stillborn males and females, and the predicted male and female abortuses left the number of products of conception lost to miscarriage.

Statistical significance of deviation of calculated numbers of miscarried males and females from expected numbers (males and females are equally susceptible to miscarriage) was assessed using Pearson's χ^2 test. All calculations were rounded to the nearest whole number to reflect the impossibility of conceiving a fraction of a person, and so in some cases annual totals are not the sum of their constituent parts. It also goes without saying that the ratios presented here address only a narrow range of biological sex, not gender, and are predicated on the simplistic assumption that XX = female and XY = male.

Supplemental table S1. Live births, stillbirths and abortions in England and Wales, 1993-2017. Numbers of males and females for live births and stillbirths reflect classifications as recorded on the relevant birth registers. Abortus sex is calculated from the total number of therapeutic and elective abortions on the assumption that the sex ratio ≤ 12 weeks of gestation is 55:45 in favour of females, and 45:55 in favour of males from ≥ 13 weeks of gestation. Total or average values are provided in the bottom rows.

Year	Live births				Stillbirths				Abortions				Total (live births + stillbirths + abortions)
	Total	Female	Male	Male live births per 1,000 female live births	Total	Female	Male	Male stillbirths per 1000 female stillbirths	Total	Female	Male	Male abortuses per 1000 female abortuses	
1993	673467	327632	345835	1056	3855	1779	2076	1167	157846	85072	72775	855	835168
1994	664726	323405	341321	1055	3813	1779	2034	1143	156539	84363	72176	856	825078
1995	648138	315950	332188	1051	3600	1688	1912	1133	154315	83211	71104	854	806053
1996	649485	315995	333490	1055	3539	1731	1808	1044	167916	90444	77472	857	820940
1997	642093	313021	329072	1051	3439	1638	1801	1100	170145	91732	78413	855	815677
1998	635901	309998	325903	1051	3417	1595	1822	1142	177871	95875	81996	855	817189
1999	621872	302617	319255	1055	3305	1578	1727	1094	173701	93634	80067	855	798878
2000	604441	294816	309625	1050	3203	1472	1731	1176	175542	94485	81057	858	783186
2001	594634	289999	304635	1050	3159	1434	1725	1203	176364	94851	81513	859	774157
2002	596122	290059	306063	1055	3372	1565	1807	1155	175932	94542	81390	861	775426
2003	621469	303041	318428	1051	3585	1711	1874	1091	181582	97557	84025	861	806636
2004	639721	311381	328340	1054	3686	1736	1950	1123	185415	99690	85725	860	828822
2005	645835	315235	330600	1049	3483	1687	1796	1065	186416	100535	85881	854	835734
2006	669601	327172	342429	1047	3602	1741	1861	1069	193737	104469	89268	854	866940
2007	690013	335525	354488	1057	3598	1691	1907	1128	198499	107139	91360	853	892110
2008	708711	345748	362963	1050	3617	1722	1895	1100	195296	105514	89782	851	907624
2009	706248	344113	362135	1052	3688	1730	1958	1132	189100	103114	85986	834	899036
2010	723165	352199	370966	1053	3714	1745	1969	1128	189574	102582	86992	848	916453
2011	723913	352939	370974	1051	3811	1791	2020	1128	189931	102787	87144	848	917655
2012	729674	355328	374346	1054	3558	1674	1884	1125	185122	100150	84972	848	918354
2013	698512	340129	358383	1054	3284	1565	1719	1098	185331	100360	84971	847	887127
2014	695233	338461	356772	1054	3254	1602	1652	1031	184571	99998	84573	846	883058
2015	697852	339716	358136	1054	3147	1498	1649	1092	185824	100649	85175	846	886823
2016	696271	339225	357046	1053	3112	1560	1552	995	185596	100501	85095	847	884979
2017	679106	331035	348071	1051	2873	1347	1526	1133	189859	102488	87371	853	871838
Total:	16656203	8114739	8541464	-	86714	41059	45655	-	4512024	2435740	2076284	-	21254941
Average:	666248	324590	341659	1053	3469	1642	1826	1112	180481	97430	83051	853	850198

Supplemental table S2. Predicted spontaneous abortions (miscarriages) in England and Wales, 1993-2017. The number of conceptions is calculated on the assumption that the sum of live births, stillbirths and elective and therapeutic abortions represents 67% of all conceptions (i.e. 33% of conception are lost). The sex ratio at conception is equal, and so the number of miscarriages can be calculated from the number of males or females conceived and the number accounted for in live birth, stillbirth or abortion statistics. Total or average values are provided in the bottom rows.

	Number of conceptions			Number of conceptions accounted for in live birth stillbirth and abortion data			Number of miscarriages			
	Total	Female	Male	Total	Female	Male	Total	Female	Male	Male miscarriages per 1000 female miscarriages
1993	1110773	555387	555387	835168	414483	420686	275605	140904	134701	956
1994	1097354	548677	548677	825078	409547	415531	272276	139130	133146	957
1995	1072050	536025	536025	806053	400849	405204	265997	135176	130822	968
1996	1091850	545925	545925	820940	408170	412770	270910	137755	133155	967
1997	1084850	542425	542425	815677	406391	409286	269173	136034	133139	979
1998	1086861	543431	543431	817189	407468	409721	269672	135963	133709	983
1999	1062508	531254	531254	798878	397829	401049	263630	133425	130205	976
2000	1041637	520819	520819	783186	390773	392413	258451	130046	128405	987
2001	1029629	514814	514814	774157	386284	387873	255472	128531	126941	988
2002	1031317	515658	515658	775426	386166	389260	255891	129492	126399	976
2003	1072826	536413	536413	806636	402309	404327	266190	134104	132086	985
2004	1102333	551167	551167	828822	412807	416015	273511	138360	135151	977
2005	1111526	555763	555763	835734	417457	418277	275792	138306	137486	994
2006	1153030	576515	576515	866940	433382	433558	286090	143133	142957	999
2007	1186506	593253	593253	892110	444355	447755	294396	148898	145498	977
2008	1207140	603570	603570	907624	452984	454640	299516	150586	148930	989
2009	1195718	597859	597859	899036	448957	450079	296682	148902	147780	992
2010	1218882	609441	609441	916453	456526	459927	302429	152915	149514	978
2011	1220481	610241	610241	917655	457517	460138	302826	152724	150102	983
2012	1221411	610705	610705	918354	457152	461202	303057	153554	149503	974
2013	1179879	589939	589939	887127	442054	445073	292752	147885	144867	980
2014	1174467	587234	587234	883058	440061	442997	291409	147172	144237	980
2015	1179475	589737	589737	886823	441863	444960	292652	147874	144777	979
2016	1177022	588511	588511	884979	441286	443693	292043	147225	144818	984
2017	1159545	579772	579772	871838	434870	436968	287707	144903	142804	986
Total:	28269072	14134536	14134536	21254941	10591538	10663403	7014131	3542998	3471133	-
Average:	1130763	565381	565381	850198	423662	426536	280565	141720	138845	980